✦ LIBER ✦

Clinical trials of bestatin for leukemia and solid tumors

✍ Scribed by K. Ota; Y. Uzuka

Book ID: 105482859
Publisher: Springer
Year: 1992
Tongue: English
Weight: 849 KB
Volume: 4
Category: Article
ISSN: 0921-299X
DOI: 10.1007/bf02174207

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evidence of publication bias in clinical

Evidence of publication bias in clinical trials of biotherapies for solid tumors

✍ Alessandro Ottaiano; Giuseppe Castello; Paolo Antonio Ascierto 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 33 KB

Progress resulting from clinical trials:

Progress resulting from clinical trials: Solid tumors in childhood cancer

✍ John N. Lukens 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 962 KB

Prospective clinical trials of biotherap

Prospective clinical trials of biotherapies in solid tumors: a 5-year survey

✍ Alessandro Ottaiano; Ernesto Mollo; Giuseppe Di Lorenzo; Carmela Pisano; Massimo 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 207 KB

Statistics of conducting clinical trials

Statistics of conducting clinical trials for children with brain tumors

✍ James M. Boyett; Teresa J. Vietti 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Phase II trial of ICRF-187 in children w

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

✍ Tribhawan Vats; Barton Kamen; Jeffrey P. Krischer 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

ICRF-187 is the ( + ) enantiomer of the racemic mixture razoxane . This compound is much more water soluble and thus could be formulated for parental use. The maximum tolerated dose in children after phase I trials was determined to be 3500 mg/MVday x 3 days. A phase II trial of ICRF-187 was done in

Immunological monitoring of the tumor im

Immunological monitoring of the tumor immunoenvironment for clinical trials

✍ Anatoli M. Malyguine; Susan L. Strobl; Michael R. Shurin 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 226 KB